Compare TSHA & VET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSHA | VET |
|---|---|---|
| Founded | 2019 | 1994 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2020 | 2004 |
| Metric | TSHA | VET |
|---|---|---|
| Price | $4.38 | $11.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $13.00 | ★ $14.79 |
| AVG Volume (30 Days) | ★ 3.2M | 1.1M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 3.31% |
| EPS Growth | ★ 5.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,773,000.00 | N/A |
| Revenue This Year | N/A | $22.90 |
| Revenue Next Year | $1,023.00 | $8.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.28 | N/A |
| 52 Week Low | $3.69 | $7.10 |
| 52 Week High | $7.30 | $14.82 |
| Indicator | TSHA | VET |
|---|---|---|
| Relative Strength Index (RSI) | 29.00 | 45.46 |
| Support Level | $4.37 | $11.14 |
| Resistance Level | $4.72 | $11.93 |
| Average True Range (ATR) | 0.26 | 0.38 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 1.38 | 24.64 |
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe while optimizing low-decline oil assets. Its operating segments are: Canada, France, Netherlands, Germany, Ireland, Australia, and CEE, each representing the oil and gas exploration operations at its assets located in these regions. The company mainly derives revenue from the production and sale of petroleum and natural gas. The majority of its revenue is generated from Canada, where the company's operations are mainly focused on the Deep Basin trend in the West Pembina region of Alberta and on the Mica property.